Marker Therapeutics Inc (MRKR)

$1.60 +0.03 (1.91%)
Market Cap 17.77M
Revenue (ttm) 6.59M
Net Income (ttm) -10.73M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -162.82%
Debt to Equity Ratio 0.00
Volume 60,400
Avg Vol 134,326
Day's Range N/A - N/A
Shares Out 11.32M
Stochastic %K 21%
Beta 1.43
Analysts Strong Sell
Price Target $8.17

Company Profile

Marker Therapeutics, Inc., a clinical-stage immuno-oncology company, engages in the development and commercialization of novel T cell-based immunotherapies for the treatment of hematological malignancies and solid tumor indications. Its multi tumor associated antigen-specific T cell technology is based on the manufacture of non-engineered tumor-specific T cells that recognize multiple tumor-associated antigens. The company also develops MT-401-OTS for the treatment of acute myeloid leukemia AND...

Industry: Biotechnology
Sector: Healthcare
Phone: 713 400 6400
Address:
2450 Holcombe Blvd, MS: BCM251, Houston, United States
MACDgou
MACDgou Jul. 17 at 2:03 PM
$MRKR Yup
0 · Reply
itsMeRich
itsMeRich Jul. 17 at 2:02 PM
$MRKR
0 · Reply
YGLD
YGLD Jul. 17 at 2:01 PM
$MRKR Needs More Volume In My Opinion Good Luck To Anyone In 🍀
0 · Reply
Stock_Catcher
Stock_Catcher Jul. 17 at 1:55 PM
$MRKR 2.25 key
1 · Reply
Awesom69Trade
Awesom69Trade Jul. 17 at 1:53 PM
$MRKR yeah baby! It’s going to $5+ soon and with data can pop to $100+!!!
2 · Reply
HitzCap
HitzCap Jul. 17 at 1:52 PM
$MRKR there it is
0 · Reply
itsMeRich
itsMeRich Jul. 17 at 1:46 PM
$MRKR no one commenting on the start of something big???
1 · Reply
stonks_2021
stonks_2021 Jul. 17 at 12:32 PM
$MRKR 30+
0 · Reply
itsMeRich
itsMeRich Jul. 17 at 12:23 PM
$MRKR nothing to see here….. just killing cancer……
0 · Reply
zwark11
zwark11 Jul. 17 at 12:10 PM
$MRKR Big pre-market moves up. Fairly heavy volume. Fingers crossed it keeps going!!
0 · Reply
Latest News on MRKR
Marker Therapeutics and Cellipont Bioservices Announce Collaboration to Advance cGMP Manufacturing of MT-601, a Multi-Antigen Recognizing T Cell Therapy for Patients with Lymphoma

Jun 17, 2025, 8:00 AM EDT - 4 weeks ago

Marker Therapeutics and Cellipont Bioservices Announce Collaboration to Advance cGMP Manufacturing of MT-601, a Multi-Antigen Recognizing T Cell Therapy for Patients with Lymphoma

Marker Therapeutics Reports that Lymphodepletion Improves the Expansion and Persistence of Multi-Antigen Recognizing T Cells in Patients with Lymphoma

May 20, 2025, 8:00 AM EDT - 2 months ago

Marker Therapeutics Reports that Lymphodepletion Improves the Expansion and Persistence of Multi-Antigen Recognizing T Cells in Patients with Lymphoma

Marker Therapeutics to Spotlight Multi-Antigen Recognizing (MAR)-T Cells in High-Profile Panel on CAR-T Cell Therapies

May 19, 2025, 8:00 AM EDT - 2 months ago

Marker Therapeutics to Spotlight Multi-Antigen Recognizing (MAR)-T Cells in High-Profile Panel on CAR-T Cell Therapies

Marker Therapeutics to Present at Canaccord Genuity's Horizons in Oncology Conference

Apr 1, 2025, 8:00 AM EDT - 3 months ago

Marker Therapeutics to Present at Canaccord Genuity's Horizons in Oncology Conference

Marker Therapeutics Reports Year-End 2024 Corporate and Financial Results

Mar 31, 2025, 8:45 AM EDT - 3 months ago

Marker Therapeutics Reports Year-End 2024 Corporate and Financial Results

Marker Therapeutics to Present at the H.C. Wainwright 3rd Annual Cell Therapy Virtual Conference

Feb 25, 2025, 7:00 AM EST - 5 months ago

Marker Therapeutics to Present at the H.C. Wainwright 3rd Annual Cell Therapy Virtual Conference

Marker Therapeutics Announces $16.1 Million Private Placement

Dec 19, 2024, 8:06 AM EST - 7 months ago

Marker Therapeutics Announces $16.1 Million Private Placement

Marker Therapeutics Provides a Clinical Update on MT-601 in Patients with Lymphoma

Dec 19, 2024, 8:05 AM EST - 7 months ago

Marker Therapeutics Provides a Clinical Update on MT-601 in Patients with Lymphoma

Marker Therapeutics Awarded $9.5 Million Grant from the Cancer Prevention & Research Institute of Texas (CPRIT) to Support the Investigation of MT-601 in Patients with Pancreatic Cancer

Dec 17, 2024, 7:00 AM EST - 7 months ago

Marker Therapeutics Awarded $9.5 Million Grant from the Cancer Prevention & Research Institute of Texas (CPRIT) to Support the Investigation of MT-601 in Patients with Pancreatic Cancer

Marker Therapeutics to Present at the 2024 Ladenburg Thalmann & Co. Virtual Oncology Innovators and Investors Symposium

Dec 10, 2024, 8:30 AM EST - 7 months ago

Marker Therapeutics to Present at the 2024 Ladenburg Thalmann & Co. Virtual Oncology Innovators and Investors Symposium

Marker Therapeutics to Present at the Citizens JMP Hematology and Oncology Summit

Nov 26, 2024, 11:00 AM EST - 8 months ago

Marker Therapeutics to Present at the Citizens JMP Hematology and Oncology Summit

Marker Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Updates

Nov 14, 2024, 4:30 PM EST - 8 months ago

Marker Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Updates

Marker Therapeutics Reports Second Quarter 2024 Financial Results and Provides Business Updates

Aug 14, 2024, 4:30 PM EDT - 1 year ago

Marker Therapeutics Reports Second Quarter 2024 Financial Results and Provides Business Updates

Marker Therapeutics Awarded $2 Million Grant from NIH in Support of Phase 1 Study Investigating MT-601 in CAR-Relapsed Patients with Non-Hodgkin's Lymphoma

Aug 12, 2024, 7:00 AM EDT - 1 year ago

Marker Therapeutics Awarded $2 Million Grant from NIH in Support of Phase 1 Study Investigating MT-601 in CAR-Relapsed Patients with Non-Hodgkin's Lymphoma

Marker Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Updates

May 15, 2024, 4:15 PM EDT - 1 year ago

Marker Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Updates

Principal Investigator from City of Hope National Medical Center Invited to Present Clinical Data from Marker Therapeutics APOLLO Study at 11th Global Summit on Hematologic Malignancies

Apr 8, 2024, 7:00 AM EDT - 1 year ago

Principal Investigator from City of Hope National Medical Center Invited to Present Clinical Data from Marker Therapeutics APOLLO Study at 11th Global Summit on Hematologic Malignancies

Marker Therapeutics Reports Year-End 2023 Corporate and Financial Results

Mar 25, 2024, 5:45 PM EDT - 1 year ago

Marker Therapeutics Reports Year-End 2023 Corporate and Financial Results

Marker Therapeutics to Present at the H.C. Wainwright 2nd Annual Cell Therapy Virtual Conference

Mar 22, 2024, 12:30 PM EDT - 1 year ago

Marker Therapeutics to Present at the H.C. Wainwright 2nd Annual Cell Therapy Virtual Conference

Marker Therapeutics Receives Approval from United States Adopted Name (USAN) Council and International Nonproprietary Names (INN) Expert Committee for “Neldaleucel” as Nonproprietary Name for MT-601

Jan 22, 2024, 7:30 AM EST - 1 year ago

Marker Therapeutics Receives Approval from United States Adopted Name (USAN) Council and International Nonproprietary Names (INN) Expert Committee for “Neldaleucel” as Nonproprietary Name for MT-601

Marker Therapeutics Announces Clinical Program Updates and Pipeline Prioritization

Jan 8, 2024, 8:24 AM EST - 1 year ago

Marker Therapeutics Announces Clinical Program Updates and Pipeline Prioritization

Marker Therapeutics Announces Participation in Biotech Showcase and the 19th Annual Non-Dilutive Funding Summit During “J.P. Morgan Week 2024”

Dec 21, 2023, 11:00 AM EST - 1 year ago

Marker Therapeutics Announces Participation in Biotech Showcase and the 19th Annual Non-Dilutive Funding Summit During “J.P. Morgan Week 2024”

Marker Therapeutics Reports Third Quarter 2023 Financial Results and Provides Business Updates

Nov 9, 2023, 5:00 PM EST - 1 year ago

Marker Therapeutics Reports Third Quarter 2023 Financial Results and Provides Business Updates

Marker Therapeutics Announces Complete Response in First Lymphoma Patient Treated with MT-601 after CAR T Relapse

Sep 11, 2023, 7:00 AM EDT - 2 years ago

Marker Therapeutics Announces Complete Response in First Lymphoma Patient Treated with MT-601 after CAR T Relapse

Marker Therapeutics to Present at the H.C. Wainwright 25th Annual Global Investment Conference

Aug 30, 2023, 8:00 AM EDT - 2 years ago

Marker Therapeutics to Present at the H.C. Wainwright 25th Annual Global Investment Conference

Marker Therapeutics Highlights Its Technology During a WBB Research Institute Webinar on CAR-T and Other Cell Therapies

Aug 17, 2023, 9:03 AM EDT - 2 years ago

Marker Therapeutics Highlights Its Technology During a WBB Research Institute Webinar on CAR-T and Other Cell Therapies

Marker Therapeutics Reports Second Quarter 2023 Financial Results and Provides Business Update

Aug 14, 2023, 4:30 PM EDT - 2 years ago

Marker Therapeutics Reports Second Quarter 2023 Financial Results and Provides Business Update

Marker Therapeutics Reports Non-Clinical Proof-of-Concept Data and Update on Clinical Readiness for the MT-401 Off-the-Shelf Program

Aug 7, 2023, 7:00 AM EDT - 2 years ago

Marker Therapeutics Reports Non-Clinical Proof-of-Concept Data and Update on Clinical Readiness for the MT-401 Off-the-Shelf Program

European Medicines Agency Grants Orphan Drug Designation for MT-401 developed by Marker Therapeutics for the Treatment of AML Patients

Jul 10, 2023, 7:00 AM EDT - 2 years ago

European Medicines Agency Grants Orphan Drug Designation for MT-401 developed by Marker Therapeutics for the Treatment of AML Patients

Marker Therapeutics Reports MT-401 Non-Clinical Data in AML Cells after Hypomethylating Agent Administration

Jun 26, 2023, 7:00 AM EDT - 2 years ago

Marker Therapeutics Reports MT-401 Non-Clinical Data in AML Cells after Hypomethylating Agent Administration

Marker Therapeutics Announces First Lymphoma Patient Treated with MT-601 in Phase 1 Clinical Trial

Jun 12, 2023, 7:00 AM EDT - 2 years ago

Marker Therapeutics Announces First Lymphoma Patient Treated with MT-601 in Phase 1 Clinical Trial

Marker Therapeutics Reports Pre-Clinical Data of its MT-601 MultiTAA-Specific T Cell Product Candidate in Lymphoma Cells

May 31, 2023, 6:30 AM EDT - 2 years ago

Marker Therapeutics Reports Pre-Clinical Data of its MT-601 MultiTAA-Specific T Cell Product Candidate in Lymphoma Cells

Marker Therapeutics Appoints Monic Stuart, M.D., as Chief Medical Officer

May 8, 2023, 7:30 AM EDT - 2 years ago

Marker Therapeutics Appoints Monic Stuart, M.D., as Chief Medical Officer

Marker Therapeutics Announces Comprehensive Non-Dilutive Agreement With CellReady™

May 1, 2023, 7:30 AM EDT - 2 years ago

Marker Therapeutics Announces Comprehensive Non-Dilutive Agreement With CellReady™

Marker Therapeutics Reports Fiscal Year 2022 Corporate and Financial Results

Mar 22, 2023, 8:10 AM EDT - 2 years ago

Marker Therapeutics Reports Fiscal Year 2022 Corporate and Financial Results

Marker Therapeutics and Lincoln Park Capital Enter into a Common Stock Purchase Agreement for up to $25 Million

Dec 13, 2022, 7:00 AM EST - 2 years ago

Marker Therapeutics and Lincoln Park Capital Enter into a Common Stock Purchase Agreement for up to $25 Million

Marker Therapeutics Awarded $2 Million Grant from U.S. FDA to Support Marker's Phase 2 ARTEMIS Trial of MT-401 in Post-Transplant AML

Sep 13, 2022, 7:00 AM EDT - 3 years ago

Marker Therapeutics Awarded $2 Million Grant from U.S. FDA to Support Marker's Phase 2 ARTEMIS Trial of MT-401 in Post-Transplant AML

Marker Therapeutics to Participate in Cantor Fitzgerald Cell and Genetic Medicines Conference

Sep 8, 2022, 7:00 AM EDT - 3 years ago

Marker Therapeutics to Participate in Cantor Fitzgerald Cell and Genetic Medicines Conference

Marker Therapeutics Reports Q2 2022 Operating and Financial Results

Aug 11, 2022, 4:22 PM EDT - 3 years ago

Marker Therapeutics Reports Q2 2022 Operating and Financial Results

Marker Therapeutics Announces FDA Clearance of IND for MT-601, the six-antigen targeted T Cell Therapy for the treatment of relapsed/refractory Non-Hodgkin Lymphoma

Aug 4, 2022, 4:37 PM EDT - 3 years ago

Marker Therapeutics Announces FDA Clearance of IND for MT-601, the six-antigen targeted T Cell Therapy for the treatment of relapsed/refractory Non-Hodgkin Lymphoma

Marker Therapeutics Reports Q1 2022 Operating and Financial Results

May 13, 2022, 7:00 AM EDT - 3 years ago

Marker Therapeutics Reports Q1 2022 Operating and Financial Results

Marker Therapeutics to Present Four Posters on its T Cell-Based Immunotherapies at the 2022 International Society for Cell & Gene Therapy Annual Meeting

May 4, 2022, 10:30 AM EDT - 3 years ago

Marker Therapeutics to Present Four Posters on its T Cell-Based Immunotherapies at the 2022 International Society for Cell & Gene Therapy Annual Meeting

Marker Therapeutics Reports Fiscal Year 2021 Operating and Financial Results

Mar 17, 2022, 5:45 PM EDT - 3 years ago

Marker Therapeutics Reports Fiscal Year 2021 Operating and Financial Results

Marker Therapeutics to Present at Two Upcoming March Investor Conferences

Mar 7, 2022, 4:05 PM EST - 3 years ago

Marker Therapeutics to Present at Two Upcoming March Investor Conferences

Why Are Marker Therapeutics Shares Trading Lower On Thursday?

Feb 17, 2022, 1:08 PM EST - 3 years ago

Why Are Marker Therapeutics Shares Trading Lower On Thursday?

Marker Therapeutics Announces Clinical Program Updates and Pipeline Expansion

Feb 16, 2022, 4:30 PM EST - 3 years ago

Marker Therapeutics Announces Clinical Program Updates and Pipeline Expansion

Marker Therapeutics to Host Clinical Program Update Conference Call and Webcast on Wednesday, February 16, 2022

Feb 8, 2022, 4:05 PM EST - 3 years ago

Marker Therapeutics to Host Clinical Program Update Conference Call and Webcast on Wednesday, February 16, 2022

Marker Therapeutics Stock Gains On FDA Orphan Drug Tag For Second MultiTAA-Cell Therapy For Pancreatic Cancer

Jan 20, 2022, 6:38 AM EST - 3 years ago

Marker Therapeutics Stock Gains On FDA Orphan Drug Tag For Second MultiTAA-Cell Therapy For Pancreatic Cancer

Marker Therapeutics Receives FDA Orphan Drug Designation for its Multi-Antigen Targeted T Cell Therapy for Pancreatic Cancer

Jan 19, 2022, 4:49 PM EST - 3 years ago

Marker Therapeutics Receives FDA Orphan Drug Designation for its Multi-Antigen Targeted T Cell Therapy for Pancreatic Cancer

Marker Therapeutics Appoints Biotech Executive Katharine Knobil, M.D., to Board of Directors

Dec 9, 2021, 7:00 AM EST - 3 years ago

Marker Therapeutics Appoints Biotech Executive Katharine Knobil, M.D., to Board of Directors

Marker Therapeutics Announces that Data from Investigator-Sponsored Phase 1 Study With its MultiTAA-Specific T Cells to be Presented at the 2021 American Society of Hematology Annual Meeting

Nov 18, 2021, 4:05 PM EST - 3 years ago

Marker Therapeutics Announces that Data from Investigator-Sponsored Phase 1 Study With its MultiTAA-Specific T Cells to be Presented at the 2021 American Society of Hematology Annual Meeting

MACDgou
MACDgou Jul. 17 at 2:03 PM
$MRKR Yup
0 · Reply
itsMeRich
itsMeRich Jul. 17 at 2:02 PM
$MRKR
0 · Reply
YGLD
YGLD Jul. 17 at 2:01 PM
$MRKR Needs More Volume In My Opinion Good Luck To Anyone In 🍀
0 · Reply
Stock_Catcher
Stock_Catcher Jul. 17 at 1:55 PM
$MRKR 2.25 key
1 · Reply
Awesom69Trade
Awesom69Trade Jul. 17 at 1:53 PM
$MRKR yeah baby! It’s going to $5+ soon and with data can pop to $100+!!!
2 · Reply
HitzCap
HitzCap Jul. 17 at 1:52 PM
$MRKR there it is
0 · Reply
itsMeRich
itsMeRich Jul. 17 at 1:46 PM
$MRKR no one commenting on the start of something big???
1 · Reply
stonks_2021
stonks_2021 Jul. 17 at 12:32 PM
$MRKR 30+
0 · Reply
itsMeRich
itsMeRich Jul. 17 at 12:23 PM
$MRKR nothing to see here….. just killing cancer……
0 · Reply
zwark11
zwark11 Jul. 17 at 12:10 PM
$MRKR Big pre-market moves up. Fairly heavy volume. Fingers crossed it keeps going!!
0 · Reply
MrTicker
MrTicker Jul. 17 at 11:30 AM
$MRKR Marker Therapeutics Collaborates With Cellipont Bioservices To Accelerate cGMP Manufacturing Of MT-601 MAR-T Cell Therapy For Lymphoma BENZINGA 7:08 AM ET 6/17/2025
0 · Reply
MGeronimo
MGeronimo Jul. 16 at 9:29 PM
$MRKR adding more on the dip at 1.50
0 · Reply
Awesom69Trade
Awesom69Trade Jul. 14 at 3:36 PM
$SONN Why can’t my stock have this pop? $MRKR
2 · Reply
flashdash
flashdash Jul. 14 at 12:30 PM
$MRKR vs. $INKT-----$MRKR has a much smaller market cap----$MRKR could be a rocketship imo on any positive annoucement.
0 · Reply
SimSimBola
SimSimBola Jul. 11 at 11:07 PM
$MRKR you conveniently left out an important bit: Mink's free float is 1/8 of Marker's. So are you willfully misguiding people or honestly ignorant?
2 · Reply
flashdash
flashdash Jul. 11 at 7:21 PM
$INKT skyrocketing....check out $MRKR.....$MRKR next?....$MRKR has low float and good balance sheet.....$MRKR has T cell tech for lymphoma and solid tumors
0 · Reply
Trak2
Trak2 Jul. 11 at 6:58 PM
$MRKR no
0 · Reply
flashdash
flashdash Jul. 11 at 6:40 PM
$INKT soaring...$MRKR next?.....is $MRKR technology similar to $INKT ?
0 · Reply
Trak2
Trak2 Jul. 11 at 2:59 PM
$MRKR look at MINK stock only 4 million shares outstanding and they released news on one patient in A phase 2 trial Who went into complete remission and the stock is exploding today, So it’s possible for us also
0 · Reply
Trak2
Trak2 Jul. 10 at 6:16 PM
$MRKR does anybody remember when the pancreatic trial starts? T thank you
1 · Reply
kshonstocks
kshonstocks Jul. 10 at 4:25 PM
$MRKR is textbook 150 dma b/o like it
0 · Reply
Awesom69Trade
Awesom69Trade Jul. 10 at 3:11 PM
$MRKR it’s gonna run to $5+ very soon, imo
1 · Reply